NeoTract, Inc. Announces Positive Coverage Decisions From Geisinger Health Plan and EmblemHealth for UroLift® Implant Procedure

Decisions Further Expand Access to Minimally Invasive Treatment for
Men with an Enlarged Prostate

PLEASANTON, Calif.–(BUSINESS WIRE)–NeoTract, Inc., a medical device company focused on addressing unmet
needs in the field of urology, today announced new positive coverage
decisions from Geisinger Health Plan and EmblemHealth, expanding access
to the UroLift^® System for the treatment of their
members with benign prostatic hyperplasia (BPH).

Geisinger Health Plan, one of the nation’s largest integrated health
services organizations, has approximately 540,000 members primarily in
Pennsylvania and with a notable presence across south New Jersey,
Delaware, Maine and West Virginia. EmblemHealth, in New York, New Jersey
and Connecticut, issued its coverage policy for the plan’s Medicare
Advantage members.

“We are pleased to see the continued expansion of access to UroLift for
millions of men across the United States who are seeking this much less
invasive treatment for BPH,” said Dave Amerson, president and CEO,
NeoTract, Inc. “That integrated healthcare systems such as Geisinger,
Kaiser Permanente, and Select Health have all embraced UroLift system
treatment is not only a testament to the improved net health outcomes
UroLift offers, but also the efficiency of care the treatment can
provide a healthcare system.”

The UroLift System is a first-line treatment that gets men off BPH
medications and allows them to avoid major surgery, while preserving
sexual function. Long-term clinical data from the LIFT randomized study
published in Urologic
Clinics of North America showed that, after four years, patients
treated with the UroLift device continue to experience symptom relief
with minimal side effects, with few patients requiring an additional
procedure for relief.¹ A second randomized clinical trial
called BPH6 demonstrated that the minimally invasive UroLift device
compares very well to transurethral resection of the prostate (TURP)
with regard to efficacy, and is superior to TURP at preserving sexual
function and offering a more rapid recovery.

Symptoms of BPH often include sleepless nights and urinary problems, and
can cause loss of productivity, depression and decreased quality of
life. Medication is often the first-line therapy for enlarged prostate,
but relief can be inadequate and temporary. Side effects of medication
treatment can include sexual dysfunction, dizziness and headaches,
prompting many patients to quit using the drugs. For these patients, the
classic alternative is surgery that cuts, heats or removes prostate
tissue to open the blocked urethra. While current surgical options can
be very effective in relieving symptoms, they can also leave patients
with permanent side effects such as urinary incontinence, erectile
dysfunction and retrograde ejaculation (dry orgasm).

About the UroLift System

The FDA-cleared UroLift System is a novel, minimally invasive technology
for treating lower urinary tract symptoms due to benign prostatic
hyperplasia (BPH). The UroLift permanent implants, delivered during a
minimally invasive transurethral outpatient procedure, relieve prostate
obstruction and open the urethra directly without cutting, heating, or
removing prostate tissue. Clinical data from a pivotal 206-patient
randomized controlled study showed that patients with enlarged prostate
receiving UroLift implants reported rapid and durable symptomatic and
urinary flow rate improvement without compromising sexual function.
Patients also experienced a significant improvement in quality of life.
Most common adverse events reported include hematuria, dysuria,
micturition urgency, pelvic pain, and urge incontinence. Most symptoms
were mild to moderate in severity and resolved within two to four weeks
after the procedure. The UroLift System is available in the U.S.,
Europe, Australia and Canada. Learn more at www.UroLift.com.

About NeoTract

NeoTract, Inc. is dedicated to developing innovative, minimally invasive
and clinically effective devices that address unmet needs in the field
of urology. The company’s initial focus is on improving the standard of
care for patients with BPH using the UroLift System, a minimally
invasive permanent implant system that treats symptoms while preserving
normal sexual function. Learn more at www.UroLift.com.

¹ Roehrborn et al. Urology Clinics 2016

Contacts

For NeoTract, Inc.:
Nicole Osmer, 650-454-0504
nicole@nicoleosmer.com